이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sinopharm Tech Holdings 미래 성장

Future 기준 확인 0/6

현재 Sinopharm Tech Holdings 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Hospitality 수익 성장	25.8%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Is Sinopharm Tech Holdings Limited's (HKG:8156) Shareholder Ownership Skewed Towards Insiders?

Feb 02

How Much Did Sinopharm Tech Holdings'(HKG:8156) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 29

How Should Investors Feel About Sinopharm Tech Holdings' (HKG:8156) CEO Remuneration?

Nov 24

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Sinopharm Tech Holdings 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SEHK:8156 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (HKD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2023	47	-29	-1	-1	N/A
9/30/2023	41	-17	N/A	N/A	N/A
6/30/2023	43	-11	5	5	N/A
3/31/2023	23	-55	N/A	N/A	N/A
12/31/2022	44	-59	7	7	N/A
9/30/2022	45	-74	N/A	N/A	N/A
6/30/2022	41	-88	-37	-37	N/A
3/31/2022	48	-98	N/A	N/A	N/A
12/31/2021	34	-106	-45	-40	N/A
9/30/2021	33	-111	N/A	N/A	N/A
6/30/2021	78	-106	-16	-6	N/A
3/31/2021	136	-160	N/A	N/A	N/A
12/31/2020	134	-158	0	27	N/A
9/30/2020	161	-162	N/A	N/A	N/A
6/30/2020	166	-161	1	24	N/A
3/31/2020	120	-49	N/A	N/A	N/A
12/31/2019	119	-45	-32	-31	N/A
9/30/2019	89	-38	N/A	N/A	N/A
6/30/2019	44	-47	-34	-34	N/A
3/31/2019	28	-42	N/A	N/A	N/A
12/31/2018	25	-49	-23	-23	N/A
9/30/2018	24	-58	N/A	N/A	N/A
6/30/2018	25	-61	-31	-30	N/A
3/31/2018	22	-156	N/A	N/A	N/A
12/31/2017	24	-164	-59	-55	N/A
9/30/2017	25	-172	N/A	N/A	N/A
6/30/2017	26	-175	N/A	-59	N/A
3/31/2017	32	-223	N/A	N/A	N/A
12/31/2016	29	-222	N/A	-52	N/A
9/30/2016	26	-218	N/A	N/A	N/A
6/30/2016	35	-207	N/A	-39	N/A
3/31/2016	27	-63	N/A	N/A	N/A
12/31/2015	78	-22	N/A	-34	N/A
9/30/2015	121	8	N/A	N/A	N/A
6/30/2015	124	19	N/A	-13	N/A
3/31/2015	135	37	N/A	N/A	N/A
12/31/2014	131	36	N/A	8	N/A
9/30/2014	103	25	N/A	N/A	N/A
6/30/2014	96	15	N/A	0	N/A
3/31/2014	90	-11	N/A	N/A	N/A
12/31/2013	52	-20	N/A	-10	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 8156 의 예상 수익 증가율이 절약률( 2.2% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: 8156 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 8156 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: 8156 의 수익이 Hong Kong 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: 8156 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 8156 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Sinopharm Tech Holdings 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Sinopharm Tech Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2023

Sinopharm Tech Holdings Provides Earnings Guidance for the Six Months Ended December 31, 2022

Sinopharm Tech Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Three Months Ended 30 September 2022

Recent updates

New minor risk - Financial data availability

Second quarter 2024 earnings released: HK$0.003 loss per share (vs HK$0.061 profit in 2Q 2023)

Sinopharm Tech Holdings Limited to Report First Half, 2024 Results on Feb 29, 2024

Sinopharm Tech Holdings Limited Announces Management Changes

Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 22, 2023

First quarter 2024 earnings released: HK$0.013 loss per share (vs HK$0.024 profit in 1Q 2023)

Sinopharm Tech Holdings Limited to Report Q1, 2024 Results on Nov 14, 2023

Full year 2023 earnings released: HK$0.001 loss per share (vs HK$0.49 loss in FY 2022)

Sinopharm Tech Holdings Limited Provides Earnings Guidance for the Year Ended 30 June 2023

Sinopharm Tech Holdings Limited to Report Fiscal Year 2023 Results on Sep 29, 2023

Sinopharm Tech Holdings Limited Appoints HEUNG Pik Lun as an Independent Non-Executive Director and A Member of the Audit Committee and the Nomination Committee

New major risk - Share price stability

Third quarter 2023 earnings released: HK$0.001 loss per share (vs HK$0.002 loss in 3Q 2022)

Sinopharm Tech Holdings Limited Announces the Resignation of LAM Kit Sun as Independent Non-Executive Director, Member of the Audit Committee and the Remuneration Committee and the Chairperson and Member of the Nomination Committee

Second quarter 2023 earnings released: EPS: HK$0.002 (vs HK$0.001 loss in 2Q 2022)

Sinopharm Tech Holdings Provides Earnings Guidance for the Six Months Ended December 31, 2022

Sinopharm Tech Holdings Limited to Report First Half, 2023 Results on Feb 14, 2023

First quarter 2023 earnings released: EPS: HK$0.001 (vs HK$0.002 loss in 1Q 2022)

Less than half of directors are independent

Sinopharm Tech Holdings Limited, Annual General Meeting, Dec 16, 2022

Sinopharm Tech Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Three Months Ended 30 September 2022

Sinopharm Tech Holdings Limited to Report Q1, 2023 Results on Nov 14, 2022

Full year 2022 earnings released: HK$0.02 loss per share (vs HK$0.025 loss in FY 2021)

Sinopharm Tech Holdings Limited to Report Fiscal Year 2022 Results on Sep 30, 2022

Sinopharm Tech Holdings Limited Announces Management Changes

Sinopharm Tech Holdings Limited Announces Management Changes

Chan Ting Resigns as CEO of Sinopharm Tech Holdings Limited

Third quarter 2022 earnings released: HK$0.002 loss per share (vs HK$0.004 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Sinopharm Tech Holdings Limited to Report First Half, 2022 Results on Feb 14, 2022

Sinopharm Tech Holdings Limited to Report First Half, 2022 Results on Feb 14, 2022

First quarter 2022 earnings released: HK$0.002 loss per share (vs HK$0.001 loss in 1Q 2021)

Full year 2021 earnings released: HK$0.025 loss per share (vs HK$0.039 loss in FY 2020)

Insider recently bought HK$15m worth of stock

Co-Founder & Non-Executive Director Tung Mei Chan has left the company

Third quarter 2021 earnings released: HK$0.004 loss per share (vs HK$0.004 loss in 3Q 2020)

Sinopharm Tech Holdings Limited (SEHK:8156) entered into a sale and purchase agreement to acquire 25% stake in Shenzhen Ficus Technology Holdings Ltd. from Sharp Associates Limited for HKD 200 million.

New 90-day high: HK$0.29

Second quarter 2021 earnings released: HK$0.002 loss per share (vs HK$0.003 loss in 2Q 2020)

Is Sinopharm Tech Holdings Limited's (HKG:8156) Shareholder Ownership Skewed Towards Insiders?

Sinopharm Tech Holdings Limited to Report First Half, 2021 Results on Feb 10, 2021

Sinopharm Tech Holdings Limited Announces Board Changes

New 90-day high: HK$0.22

How Much Did Sinopharm Tech Holdings'(HKG:8156) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: HK$0.20

How Should Investors Feel About Sinopharm Tech Holdings' (HKG:8156) CEO Remuneration?

First quarter 2021 earnings released: HK$0.001 loss per share

Sinopharm Tech Holdings Limited to Report Q1, 2021 Results on Nov 12, 2020

Full year earnings released - HK$0.039 loss per share

Sinopharm Tech Holdings Limited(SEHK:8156) dropped from S&P Global BMI Index

Sinopharm Tech Holdings Limited to Report Fiscal Year 2020 Results on Sep 29, 2020

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견